The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20071987
The Journal of Experimental Medicine, Vol. 205, No. 8, 1729-1737
The Rockefeller University Press, 0022-1007 $30.00
© Vogt et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2318K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogt, G.
Right arrow Articles by Casanova, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogt, G.
Right arrow Articles by Casanova, J.-L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BRIEF DEFINITIVE REPORT

Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation

Guillaume Vogt1,2, Jacinta Bustamante1,2, Ariane Chapgier1,2, Jacqueline Feinberg1,2, Stephanie Boisson Dupuis1,2, Capucine Picard1,2,3, Nizar Mahlaoui4, Laure Gineau1,2, Alexandre Alcaïs1,2, Christophe Lamaze6, Jennifer M. Puck7, Geneviève de Saint Basile5, Claudia Djambas Khayat8, Raymond Mikhael8, and Jean-Laurent Casanova1,2,4

1 Laboratory of Human Genetics of Infectious Diseases, U550, Institut National de la Santé et de la Recherche Médicale (INSERM), 75015 Paris, France
2 University Paris René Descartes, Necker Medical School, 75015 Paris, France
3 Study Center of Primary Immunodeficiencies, APHP, and 4 Pediatric Immunology-Hematology Unit, Necker Hospital, 75015 Paris, France
5 Laboratory of Normal and Pathological Development of the Immune System, U768, INSERM, Necker-Enfants Malades Hospital, 75015 Paris, France
6 Trafic, Signaling and Delivery Laboratory, UMR144 Curie Centre National de la Recherche Scientifique, Institut Curie, 75005 Paris, France
7 Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143
8 Department of Pediatrics, Hotel Dieu de France Hospital, 90262 Beirut, Lebanon

CORRESPONDENCE Guillaume Vogt: vogt{at}necker.fr OR Jean-Laurent Casanova: casanova{at}necker.fr

Germline mutations may cause human disease by various mechanisms. Missense and other in-frame mutations may be deleterious because the mutant proteins are not correctly targeted, do not function correctly, or both. We studied a child with mycobacterial disease caused by homozygosity for a novel in-frame microinsertion in IFNGR2. In cells transfected with the mutant allele, most of the interferon {gamma} receptor 2 (IFN-{gamma}R2) protein was retained within the cell, and that expressed on the cell surface had an abnormally high molecular weight (MW). The misfolding mutation was not gain-of-glycosylation, as it created no new N-glycosylation site. The mutant IFNGR2 allele was null, as the patient's cells did not respond to IFN-{gamma}. Based on the well-established relationship between protein N-glycosylation and protein quality control processes, we tested 29 compounds affecting maturation by N-glycosylation in the secretory pathway. Remarkably, up to 13 of these compounds reduced the MW of surface-expressed mutant IFN-{gamma}R2 molecules and restored cellular responsiveness to IFN-{gamma}. Modifiers of N-glycosylation may therefore complement human cells carrying in-frame and misfolding, but not necessarily gain-of-glycosylation, mutations in genes encoding proteins subject to trafficking via the secretory pathway. Some of these compounds are available for clinical use, paving the way for clinical trials of chemical complementation for various human genetic traits.


A. Chapgier, J. Feinberg, and S. Boisson Dupuis contributed equally to this paper.

© 2008 Vogt et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS